serotonin syndrome (serotonism)
Jump to navigation
Jump to search
Etiology
- excess serotonin or increased sensitivity to serotonin
- increased serotonin production
- L tyrptophan, cocaine, amphetamines, phentermine
- inhibition of serotonin reuptake
- SSRI, SNRI, tricyclic antidepressants (TCA), bupropion, nefazodone, trazodone, dextromethorphan, meperidine, pentazocine, St John's wort, tramadol, phentermine, granisetron, ondansetron, chlopheniramine
- inhibition of serotonin metabolism
- increased serotonin release
- dextromethorphan, meperidine, oxycodone, L-dopa, amphetamines, phentermine, methyleledioxymethamphetamine (MDMA, Ecstasy), mirtazapine
- serotonin receptor agonists
- inhibition of elimination of serotonin via inhibition of cyt P450 isozymes
- CYP2D6
- inhibitors: fluoxetine, sertraline
- substrates: dextromethorphan, oxycodone, phentermine, risperidone, tramadol
- CYP3A4
- inhibitors: ciprofloxacin, ritonavir
- substrates: methadone, oxycodone, venlafaxine
- CYP2C19
- inhibitors: fluconazole
- substrates: citalopram
- CYP2D6
- generally occurs when 2 or more drugs that affect the serotonin system through different mechanisms are prescribed[3]
- monoamine oxidase inhibitors (MAOi) with SSRI, SNRI, TCA, opiates
- SSRI with MAOi, SNRI, TCA, opiates, or triptans
- SNRI with MAOi, TCA, opiates, or triptans
- venlafaxine with lithium carbonate, calcineurin inhibitors, mirtazqpine, or tranylcypromine
- venlafaxine with mirtazapine & tramadol, amitriptyline & meperidine, methadone & fluoxetine or sertraline, tramadole & trazodone & quetiapine
- opiates with MAOi, SSRI, SNRI or triptans
- tramadol with mirtazapine & olanzapine
- dextromethorphan with SSRI, amitriptyline, or chlorpheniramine
- olanzapine with lithium carbonate & citalopram
- risperidone with fluoxetine or paroxetine
- ciprofloxacin with venlafaxine & methadone
- fluconazole with citalopram
- linezolid with SSRI or tapentodol
Pathology
- autonomic hyperactivity
- hemodynamic changes
- neuromuscular disorder
- mental status changes
- potentially life-threatening[10]
Clinical manifestations
- mild:
- headache
- dizziness
- agitation, restlessness, anxiety
- confusion, inattention
- ataxia
- neuromuscular hyperexcitability
- myoclonus (spontaneous clonus), muscle twitching, muscle rigidity
- especially lower extremities
- hyperreflexia
- tremor
- shivering
- hyperthermia, due to excessive muscular activity
- temperature may be > 105.8 F (41C)[10]
- myoclonus (spontaneous clonus), muscle twitching, muscle rigidity
- ocular clonus
- slow continuous horizontal eye movements
- hypertension or hypotension
- tachycardia, tachypnea
- diarrhea (late manifestation)
- mydriasis
- onset within 24 hours of initiating or increasing dose of offending agent - average onset < 12 hours[10]
- gastrointestinal prodrome, hyperactive bowel sounds
- sleep disturbance[10]
Diagnostic criteria
- see Hunter criteria
Complications
Management
- discontinuation of offending agent(s)
- most cases resolve in 24-72 hours
- supportive care
- oxygen therapy
- intravenous fluids
- cardiac monitoring, including QTc & QRS duration[10]
- external cooling if temperature > 40 C
- esmolol for hypertension
- activated charcoal to assist with gastrointestinal decontamination may be considered
- severe cases
- sedation, paralyzing agents, mechanical ventilation may be required in cases of recent exposure
- benzodiazepine
- serotonin antagonists have been used (no strong supporting evidence for their use)
- antipyretic therapy NOT recommended
More general terms
References
- ↑ Kaiser Permanente, Northern California Regional Pharmacy & Therapeutics Committee
- ↑ Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
- ↑ 3.0 3.1 Prescriber's Letter 13(9): 2006 Serotonin Syndrome Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220905&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 14, 17. American College of Physicians, Philadelphia 2006. 2015
- ↑ Prescriber's Letter 16(10): 2009 Facts About Serotonin Syndrome Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251026&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2010 Feb;50(2):264-72 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19925619
- ↑ Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. BMC Neurol. 2016 Jul 12;16:97. doi:http://dx.doi.org/ 10.1186/s12883-016-0616-1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27406219 Free PMC Article
- ↑ Dobry Y, Rice T, Sher L. Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. Int J Adolesc Med Health. 2013;25(3):193-9. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24006318
- ↑ Paauw DS Why Is Serotonin Syndrome on the Rise? Medscape - Dec 02, 2020 https://www.medscape.com/viewarticle/941567
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 Sinert RH Fast Five Quis: Serotonin Syndrome Medscape. 2121. June 4. https://reference.medscape.com/viewarticle/951841
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20 PMID: https://www.ncbi.nlm.nih.gov/pubmed/15784664 Review https://www.nejm.org/doi/10.1056/NEJMra041867 - ↑ Khan SS, Cole SP. Serotonin Syndrome. Medscape. 2020. Sept 21 https://emedicine.medscape.com/article/2500075-overview
- ↑ Foong AL, Grindrod KA, Patel T et al. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician. 2018;64(10):720-727 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30315014 PMCID: PMC6184959 Free PMC article
- ↑ Scotton WJ, Hill LJ, Williams AC et al. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019;12:1178646919873925 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31523132 PMCID: PMC6734608 Free PMC article https://journals.sagepub.com/doi/10.1177/1178646919873925
- ↑ Uddin MF, Alweis R, Shah SR et al. Controversies in serotonin syndrome diagnosis and management: a review. J Clin Diagn Res. 2017;11(9):OE05-OE07 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29207768 PMCID: PMC5713790 Free PMC article https://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2017&volume=11&issue=9&page=OE05&issn=0973-709x&id=10696
- ↑ Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology (Berl). 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34251464